Table 4.
HGP-HAIP interaction added to multivariate analysis for OS, PFS, hPFS
| Univariable | p value | Multivariable | p value | |
|---|---|---|---|---|
| Overall survival (n = 496) | ||||
| Age < 65 years | 0.73 [0.62–0.86] | < 0.001 | 1.01 [0.73–1.39] | 0.95 |
| ASA > II | 0.95 [0.80–1.13] | 0.56 | 1.08 [0.80–1.47] | 0.62 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 0.84 [0.69–1.03] | 0.10 | 0.83 [0.59–1.18] | 0.30 |
| Rectum | 0.83 [0.66–1.04] | 0.11 | 0.86 [0.57–1.29] | 0.46 |
| Preoperative systemic CTx | 1.75 [1.40–2.19] | < 0.001 | 1.67 [1.13–2.47] | < 0.01 |
| Number of CRLM | 1.09 [1.06–1.12] | < 0.001 | 1.10 [1.04–1.16] | < 0.01 |
| Diameter of largest CRLM (cm) | 1.04 [1.02–1.07] | < 0.01 | 1.08 [1.03–1.14] | < 0.001 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.76 | 1.00 [1.00–1.00] | 0.63 |
| Disease-free interval (months) | 1.00 [0.99–1.00] | 0.54 | 1.00 [0.98–1.01] | 0.50 |
| Nodal status primary tumor | 1.45 [1.22–1.73] | < 0.001 | 2.01 [1.42–2.83] | < 0.001 |
| R1 resection | 1.68 [1.36–2.07] | < 0.001 | 1.52 [1.01–2.30] | 0.05 |
| KRAS mutated | 1.71 [1.32–2.21] | < 0.001 | 1.64 [1.21–2.22] | < 0.01 |
| dHGP (vs. non-dHGP) | 0.71 [0.56–0.89] | < 0.01 | 0.47 [0.27–0.82] | < 0.01 |
| HAIP chemotherapy | 0.66 [0.52–0.83] | < 0.001 | 0.60 [0.44–0.83] | < 0.01 |
| Interaction term: dHGP*HAIP | 0.77 [0.44–1.32] | 0.34 | 1.06 [0.47–2.36] | 0.90 |
| Progression-free survival | ||||
| Age < 65 years | 1.01 [0.88–1.16] | 0.84 | 1.32 [1.02–1.69] | 0.03 |
| ASA >II | 0.95 [0.83–1.09] | 0.46 | 1.11 [0.88–1.40] | 0.38 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 1.07 [0.90–1.27] | 0.43 | 1.29 [0.97–1.70] | 0.08 |
| Rectum | 1.12 [0.93–1.35] | 0.21 | 1.40 [1.02–1.91] | 0.04 |
| Preoperative systemic CTx | 1.65 [1.39–1.96] | < 0.001 | 1.50 [1.12–1.99] | < 0.01 |
| Number of CRLM | 1.11 [1.08–1.13] | < 0.001 | 1.15 [1.10–1.20] | < 0.001 |
| Diameter of largest CRLM (cm) | 1.04 [1.02–1.06] | < 0.001 | 1.08 [1.03–1.12] | < 0.001 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.04 | 1.00 [1.00–1.00] | 0.99 |
| Disease-free interval (months) | 0.99 [0.99–1.00] | < 0.01 | 0.99 [0.98–1.00] | 0.22 |
| Nodal status primary tumor | 1.38 [1.20–1.59] | < 0.001 | 1.58 [1.24–2.02] | < 0.001 |
| R1 resection | 1.51 [1.26–1.82] | < 0.001 | 1.27 [0.91–1.77] | 0.16 |
| KRAS mutated | 1.63 [1.35–1.97] | < 0.001 | 1.73 [1.37–2.18] | < 0.001 |
| dHGP (vs. non-dHGP) | 0.58 [0.48–0.70] | < 0.001 | 0.47 [0.32–0.70] | < 0.001 |
| HAIP chemotherapy | 0.65 [0.55–0.78] | < 0.001 | 0.50 [0.39–0.64] | < 0.001 |
| Interaction term: dHGP*HAIP | 1.01 [0.67–1.52] | 0.95 | 1.29 [0.72–2.32] | 0.40 |
| Hepatic progression-free survival | ||||
| Age < 65 years | 0.97 [0.84–1.13] | 0.73 | 1.29 [0.98–1.71] | 0.07 |
| ASA >II | 0.92 [0.80–1.07] | 0.29 | 1.33 [1.03–1.73] | 0.03 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 1.08 [0.90–1.28] | 0.43 | 1.14 [0.85–1.55] | 0.38 |
| Rectum | 1.07 [0.87–1.30] | 0.52 | 1.26 [0.89–1.78] | 0.20 |
| Preoperative systemic CTx | 1.83 [1.51–2.22] | < 0.001 | 1.34 [0.97–1.85] | 0.08 |
| Number of CRLM | 1.13 [1.10–1.15] | < 0.001 | 1.15 [1.10–1.21] | < 0.001 |
| Diameter of largest CRLM (cm) | 1.01 [0.99–1.04] | 0.31 | 1.05 [1.00–1.10] | 0.05 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.86 | 1.00 [1.00–1.00] | 0.36 |
| Disease-free interval (months) | 0.99 [0.99–1.00] | < 0.001 | 0.99 [0.98–1.00] | 0.26 |
| Nodal status primary tumor | 1.36 [1.17–1.58] | < 0.001 | 1.76 [1.33–2.32] | < 0.001 |
| R1 resection | 1.56 [1.29–1.89] | < 0.001 | 1.17 [0.80–1.71] | 0.41 |
| KRAS mutated | 1.40 [1.14–1.73] | < 0.01 | 1.42 [1.10–1.83] | < 0.01 |
| dHGP (vs. non-dHGP) | 1.67 [1.37–2.04] | < 0.001 | 1.53 [1.01–2.32] | 0.05 |
| HAIP chemotherapy | 0.63 [0.42–0.94] | 0.02 | 0.57 [0.32–1.01] | 0.05 |
| Interaction term: dHGP*HAIP | 0.80 [0.51–1.24] | 0.31 | 0.79 [0.42–1.49] | 0.46 |
Bold values are statistically significant (p < 0.05)